Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by equities researchers at Goldman Sachs Group Inc. in a report released on Wednesday. They presently have a GBX 6,300 ($77.97) price target on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective would suggest a potential upside of 21.72% from the company’s previous close.
Other equities analysts also recently issued reports about the company. HSBC reduced their target price on Shire PLC from GBX 5,250 ($64.98) to GBX 5,200 ($64.36) and set a ” hold” rating on the stock in a research report on Wednesday, September 28th. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research report on Tuesday, June 14th. Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,600 ($69.31) target price on shares of Shire PLC in a research report on Friday, July 1st. Berenberg Bank reiterated a “buy” rating and set a GBX 5,800 ($71.78) target price on shares of Shire PLC in a research report on Wednesday, July 6th. Finally, Liberum Capital increased their target price on Shire PLC from GBX 4,700 ($58.17) to GBX 5,500 ($68.07) and gave the stock a “buy” rating in a research report on Wednesday, July 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have issued a buy rating to the company. Shire PLC currently has an average rating of “Buy” and a consensus target price of GBX 5,841.33 ($72.29).
Shire PLC (LON:SHP) opened at 5176.00 on Wednesday. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,377.00. The stock’s 50 day moving average price is GBX 5,005.94 and its 200-day moving average price is GBX 4,595.24. The firm’s market capitalization is GBX 35.34 billion.
The company also recently announced a dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 8th were given a GBX 3.51 ($0.04) dividend. The ex-dividend date was Thursday, September 8th. This represents a dividend yield of 0.07%.
In other news, insider Dominic Blakemore bought 133 shares of the firm’s stock in a transaction dated Friday, September 30th. The stock was bought at an average price of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.